“Medannex is a fantastic example of an ambitious Scottish company that’s developing innovative new treatments for patients globally.”

Jim Watson, Director of
Innovation & Enterprise
Services at Scottish Enterprise

Medannex Ltd is a privately-owned, preclinical-stage
biopharmaceutical company based in Edinburgh, Scotland.

Established in 2009 by serial life sciences entrepreneur Professor Chris Wood (founder of Nucana Biomed, Bioenvision and 30 Technology), Medannex is developing therapeutic antibodies that target annexin-A1, to provide new treatment options for people affected by cancers and autoimmune diseases.

The Medannex team works in conjunction with internationally renowned experts at leading UK universities. In particular, we are collaborating with teams at University College London (led by Professor David Isenberg and Professor Claudia Mauri), the University of Glasgow (under the directorship of Professor Carl Goodyear) and Anglia Ruskin University (under the supervision of Professor Chris Parris).

“Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”

Dr Stefan Symeonides, head of Phase I Trials at the CRUK Edinburgh Centre

Medannex is undergoing rapid expansion in preparation for clinical trials, guided by Dr Stefan Symeonides, who leads the Cancer Research UK Edinburgh Centre Phase I Trials Unit.

A recent Series B investment of £11million, combined with grant funding from both Innovate UK and SMART: SCOTLAND, will take Medannex to a first-in-human study in 2021.

Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.